A Phase II Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) [masoprocol] in Non-Metastatic Recurrent Prostate Cancer

Trial Profile

A Phase II Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) [masoprocol] in Non-Metastatic Recurrent Prostate Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Masoprocol (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Apr 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 20 Mar 2012 Actual patient number is 12 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top